NEWPORT INTERNATIONAL JOURNAL OF SCIENTIFIC AND EXPERIMENTAL SCIENCES (NIJSES)

Volume 7 Issue 2 Page 16-22, 2026

ONLINE ISSN:2992-5819 PRINT ISSN:2992-6149

Open Access

https://doi.org/10.59298/NIJSES/2026/72.1622

Inflammation-Responsive Nanomaterials for Controlled Drug Release in Obesity-Related Chronic Inflammatory States

Muhindo Edgar

Department of Pharmacy Kampala International University Uganda
Email: edgar.muhindo@studwc.kiu.ac.ug

ABSTRACT

Obesity is characterized by chronic low-grade inflammation that plays a central role in the development of insulin resistance, type 2 diabetes, cardiovascular disease, and other components of metabolic syndrome. This inflammatory milieu is driven largely by dysfunctional white adipose tissue, immune cell infiltration, and sustained production of pro-inflammatory mediators. Conventional pharmacological interventions often fail to adequately target inflamed tissues and are associated with systemic side effects, reduced efficacy, and poor patient adherence. In this context, inflammation-responsive nanomaterials have emerged as a promising strategy for controlled, site-specific drug delivery in obesity-related chronic inflammatory states. These smart nanomaterials are engineered to respond to inflammatory cues such as acidic pH, elevated reactive oxygen species, proteolytic enzymes, and inflammatory cytokines, enabling precise and on-demand drug release at diseased sites. This review provides a comprehensive overview of the pathophysiological basis of obesity-associated inflammation, principles of inflammation-responsive nanomaterial design, and key nanotechnological platforms developed for controlled drug release. We discuss current preclinical evidence supporting their therapeutic potential, address major translational challenges, and highlight future perspectives for integrating inflammation-responsive nanomedicine into metabolic disease management. Harnessing inflammation-triggered drug delivery systems may represent a paradigm shift toward safer, more effective, and personalized therapies for obesity-related chronic inflammatory disorders.

Keywords: Inflammation-responsive nanomaterials; Obesity; Chronic inflammation; Controlled drug release; Metabolic syndrome

INTRODUCTION

Obesity has evolved into one of the most significant global health challenges of the twenty-first century, affecting both developed and developing nations[1–5]. Beyond excessive fat accumulation, obesity is now recognized as a chronic inflammatory disease characterized by sustained low-grade inflammation that underpins its metabolic complications. This inflammatory state contributes directly to insulin resistance, type 2 diabetes mellitus, cardiovascular disease, non-alcoholic fatty liver disease, and certain cancers. Central to this process is dysfunctional white adipose tissue, which undergoes profound structural, cellular, and molecular changes during obesity[6–8].

In healthy individuals, white adipose tissue serves as an energy reservoir and an endocrine organ that secretes adipokines involved in metabolic homeostasis[9]. However, excessive caloric intake leads to adipocyte hypertrophy, local hypoxia, endoplasmic reticulum stress, and adipocyte death. These events initiate immune cell recruitment, particularly pro-inflammatory macrophages, which surround dead adipocytes to form crown-like structures. The resulting adipose tissue microenvironment is enriched with inflammatory mediators such as tumor necrosis factor-α, interleukin-6, monocyte chemoattractant protein-1, and reactive oxygen species. These signals disrupt insulin signaling pathways locally and systemically, driving metabolic dysfunction[6, 10].

Despite advances in pharmacotherapy for obesity and its complications, current treatments largely rely on systemic drug administration. Such approaches often fail to achieve sufficient drug concentrations at inflamed sites while increasing off-target exposure and adverse effects[11]. Anti-inflammatory drugs, insulin sensitizers, and lipid-lowering agents frequently exhibit limited efficacy due to poor tissue specificity, rapid clearance, or dose-limiting toxicity. These limitations have intensified interest in innovative drug delivery systems capable of selectively targeting inflamed tissues and releasing therapeutic agents in a controlled manner[12, 13].

Nanotechnology offers transformative opportunities to overcome these challenges. Nanomaterials can be engineered with precise physicochemical properties that enhance drug solubility, stability, circulation time, and tissue penetration. More importantly, recent advances have led to the development of "smart" or stimuli-responsive nanomaterials that respond dynamically to pathological microenvironments[14–17]. In obesity-related inflammation, local biochemical cues such as acidic pH, elevated reactive oxygen species, proteases, and inflammatory enzymes provide exploitable triggers for targeted drug release.

Inflammation-responsive nanomaterials are designed to remain stable during systemic circulation but undergo structural or chemical changes upon encountering inflammatory signals, thereby releasing their therapeutic payload specifically at diseased sites[18–21]. This approach maximizes therapeutic efficacy while minimizing systemic toxicity[10, 22]. Such systems have been explored for delivering anti-inflammatory agents, antioxidants, insulin sensitizers, nucleic acids, and biologics directly to inflamed adipose tissue and associated organs. This review focuses on inflammation-responsive nanomaterials developed for controlled drug release in obesity-related chronic inflammatory states. We first outline the molecular and cellular features of obesity-associated inflammation that enable stimulus-responsive targeting. We then discuss design principles, major classes of inflammation-responsive nanomaterials, and their therapeutic applications. Finally, we examine current limitations and future directions for translating these technologies into clinical practice.

2. Obesity-Related Chronic Inflammation: Molecular and Cellular Triggers

Chronic inflammation in obesity is a complex, multifactorial process driven by metabolic stress, immune dysregulation, and tissue remodeling[23]. Unlike acute inflammation, obesity-associated inflammation is persistent, low-grade, and systemic, yet sufficient to disrupt metabolic homeostasis. White adipose tissue is the primary site of inflammatory initiation, although secondary involvement of the liver, skeletal muscle, pancreas, and vasculature amplifies disease progression[23].

Adipocyte hypertrophy is a key initiating factor. As adipocytes expand beyond their vascular supply, localized hypoxia develops, activating hypoxia-inducible factor-1α and promoting pro-inflammatory gene expression[24]. Concurrently, lipid overload induces endoplasmic reticulum stress and mitochondrial dysfunction, resulting in excessive production of reactive oxygen species. These oxidative signals act as danger-associated molecular patterns that activate innate immune pathways[24].

Macrophage infiltration is a hallmark of inflamed adipose tissue. In lean individuals, adipose tissue macrophages predominantly exhibit an anti-inflammatory M2 phenotype. Obesity shifts macrophage polarization toward the pro-inflammatory M1 phenotype, characterized by elevated secretion of cytokines such as TNF-α, IL-6, and IL-1β. These cytokines interfere with insulin receptor signaling through activation of stress kinases, including JNK and IKKβ, leading to insulin resistance[25–27].

Other immune cells, including neutrophils, $CD8^+$ T cells, B cells, and mast cells, also contribute to the inflammatory network[28]. Proteolytic enzymes such as matrix metalloproteinases and cathepsins are upregulated, facilitating extracellular matrix remodeling but also serving as biochemical markers of inflammation. Additionally, the inflamed microenvironment becomes mildly acidic due to increased glycolytic metabolism and impaired perfusion[28].

Collectively, elevated reactive oxygen species, acidic pH, inflammatory enzymes, and cytokines create a unique pathological signature that distinguishes inflamed adipose tissue from healthy tissue. These molecular features provide ideal triggers for inflammation-responsive nanomaterials, enabling selective drug release in obesity-associated inflammatory sites.

3. Principles of Inflammation-Responsive Nanomaterial Design

Inflammation-responsive nanomaterials are engineered to sense and respond to specific pathological cues present in inflamed tissues. Their design integrates materials science, pathophysiology, and pharmacology to achieve spatiotemporal control over drug release[29–31]. The fundamental principle is stability under physiological conditions combined with rapid activation in inflammatory microenvironments.

One common strategy involves pH-responsive materials. Inflamed tissues often exhibit slightly acidic pH due to hypoxia and increased anaerobic metabolism[32]. Nanocarriers incorporating acid-labile bonds or pH-sensitive polymers undergo structural destabilization or bond cleavage under acidic conditions, triggering drug release[32]. Reactive oxygen species-responsive nanomaterials exploit the elevated oxidative stress characteristic of obesity-related inflammation. These systems incorporate ROS-cleavable linkages such as thioketal or boronic ester bonds, which degrade in high-ROS environments, releasing encapsulated therapeutics selectively at inflamed sites[32].

Enzyme-responsive nanomaterials are designed to respond to proteases overexpressed during inflammation, including matrix metalloproteinases and cathepsins[33]. Peptide linkers cleavable by these enzymes enable precise activation of drug release in inflamed adipose tissue.

Cytokine-responsive systems represent an emerging approach, where nanomaterials are engineered to respond indirectly to inflammatory signaling cascades. Surface modifications that interact with activated immune cells can enhance uptake and intracellular release within macrophages[10, 34, 35].

Importantly, inflammation-responsive nanomaterials can be multifunctional, integrating multiple stimuli to enhance specificity. Such combinatorial responsiveness improves selectivity and reduces unintended drug leakage, making these systems particularly attractive for chronic diseases like obesity.

4. Types of Inflammation-Responsive Nanomaterials for Controlled Drug Release

Several classes of nanomaterials have been developed and optimized for inflammation-triggered drug delivery in obesity-related disorders, reflecting the complex and multifactorial nature of obesity-associated inflammation[36]. Among these platforms, polymeric nanoparticles are the most extensively studied due to their versatility, biodegradability, and capacity for precise physicochemical tuning. Biocompatible polymers such as poly(lactic-co-glycolic acid) (PLGA), polyethylene glycol (PEG)-based copolymers, and poly(β-amino esters) can be readily functionalized with stimulus-sensitive moieties that respond to inflammatory cues such as acidic pH, elevated enzyme activity, or increased reactive oxygen species (ROS) levels[37, 38]. These features allow controlled and site-specific drug release within inflamed adipose tissue, enhancing therapeutic efficacy while reducing systemic exposure.

Lipid-based nanocarriers, including liposomes and nanostructured lipid carriers, offer distinct advantages such as excellent biocompatibility, biomimetic properties, and high drug-loading capacity for both hydrophilic and hydrophobic agents[39–41]. Their structural similarity to biological membranes facilitates cellular uptake and minimizes immunogenicity. The incorporation of oxidation-sensitive lipids into these carriers enables ROS-triggered membrane destabilization, resulting in selective payload release at sites of oxidative stress commonly observed in obese adipose tissue.

Inorganic nanomaterials, such as mesoporous silica nanoparticles and cerium oxide nanoparticles, provide superior structural stability and unique functional properties. Mesoporous silica nanoparticles offer high surface area and tunable pore sizes, allowing efficient drug encapsulation and controlled release[42]. Cerium oxide nanoparticles, in particular, possess intrinsic antioxidant activity through redox cycling, enabling them to simultaneously serve as drug carriers and modulators of oxidative stress[42].

Additionally, hydrogel-based nanocomposites represent an emerging platform for sustained and inflammation-responsive drug delivery[43]. These systems release therapeutic agents through controlled network degradation in response to inflammatory stimuli. Increasingly, hybrid nanocarrier systems that integrate polymeric, lipid, and inorganic components are being explored to achieve synergistic responsiveness, enhanced stability, and multifunctionality, thereby advancing the therapeutic potential of nanomedicine in obesity-related disorders[43].

5. Therapeutic Applications in Obesity-Related Chronic Inflammatory States

Inflammation-responsive nanomaterials have emerged as a versatile and highly promising platform for the targeted delivery of diverse therapeutic agents in the management of obesity and its associated metabolic complications[44]. Obesity is characterized by chronic low-grade inflammation within adipose tissue, driven by immune cell infiltration, oxidative stress, and dysregulated cytokine signaling. By exploiting these pathological features, inflammation-responsive nanocarriers enable site-specific drug release, thereby enhancing therapeutic efficacy while minimizing off-target effects[24, 25].

A wide range of anti-inflammatory agents has been investigated using nanotechnology-based delivery systems. Conventional anti-inflammatory drugs, including corticosteroids, non-steroidal anti-inflammatory drugs (NSAIDs), and cytokine inhibitors, often exhibit limited clinical utility due to systemic immunosuppression and adverse side effects when administered chronically[45]. Inflammation-responsive nanomaterials allow these agents to be released selectively within inflamed adipose tissue, reducing systemic exposure and improving safety profiles. This localized delivery approach has been shown to attenuate pro-inflammatory cytokine production, suppress immune cell infiltration, and improve adipose tissue homeostasis in preclinical obesity models[45].

Oxidative stress, a key contributor to insulin resistance and metabolic dysfunction in obesity, represents another important therapeutic target. Reactive oxygen species (ROS)-responsive nanocarriers have been developed to deliver antioxidants directly to sites of excessive oxidative stress. By releasing antioxidant compounds in response to elevated ROS levels, these nanomaterials effectively neutralize free radicals, reduce lipid peroxidation, and restore redox balance[46–49]. This targeted mitigation of oxidative stress has been associated with improved insulin signaling, enhanced glucose uptake, and reduced inflammatory signaling in adipocytes and peripheral tissues.

Nanoparticle-mediated delivery has also been applied to insulin sensitizers, such as thiazolidinediones, which are widely used to improve insulin sensitivity but are often limited by adverse cardiovascular effects[50]. Encapsulation within inflammation-responsive nanocarriers enhances drug accumulation in adipose tissue, allowing lower therapeutic doses to achieve comparable or superior metabolic benefits. This targeted approach not only improves insulin responsiveness but also reduces systemic drug exposure, thereby minimizing the risk of cardiovascular complications[50].

Beyond small-molecule therapeutics, gene-based interventions have gained increasing attention. Small interfering RNA (siRNA) and other nucleic acid-based therapies targeting key inflammatory mediators, such as TNF-α, IL-6, and NF-κB signaling components, have demonstrated promising results when delivered via enzyme-responsive or pH-sensitive nanocarriers[51]. These delivery systems protect genetic payloads from degradation and ensure controlled release within inflamed tissues, leading to efficient gene silencing and sustained anti-inflammatory effects.

Additionally, macrophage-targeted nanomedicine represents a novel and impactful strategy in obesity management. Adipose tissue macrophages play a central role in sustaining inflammation by adopting a pro-inflammatory (M1) phenotype. Nanoparticles designed to selectively target macrophages can modulate immune polarization, promoting a shift toward the anti-inflammatory (M2) phenotype[51]. This immune reprogramming reduces cytokine secretion, improves adipocyte function, and contributes to systemic metabolic improvements.

Collectively, these inflammation-responsive nanotherapeutic strategies have demonstrated significant improvements in metabolic parameters, including insulin sensitivity, lipid metabolism, and inflammatory burden, across multiple preclinical obesity models. While further clinical validation is required, these findings underscore the substantial potential of nanotechnology-driven precision therapies in addressing the complex inflammatory landscape of obesity.

6. Challenges and Translational Limitations

Despite the encouraging progress observed in nanotechnology-based and inflammation-targeted therapeutic strategies, several critical barriers continue to hinder their successful translation from bench to bedside. One of the most significant challenges relates to long-term biocompatibility and safety[52]. While many nanomaterials demonstrate favorable short-term efficacy and tolerability in experimental models, their long-term behavior within biological systems remains insufficiently understood. Nanoparticle accumulation in vital organs such as the liver, spleen, kidneys, and lungs raises concerns regarding chronic toxicity, immunogenicity, and unintended inflammatory responses[53]. These issues are particularly pronounced in the context of chronic inflammatory diseases, obesity-related disorders, and metabolic syndromes, where prolonged or lifelong treatment may be required.

Another major limitation is the inter-individual variability in inflammatory and metabolic profiles. Inflammation is a highly dynamic and patient-specific process influenced by genetics, epigenetic regulation, lifestyle factors, microbiome composition, and comorbid conditions[53]. This heterogeneity complicates the prediction of therapeutic responsiveness and may result in variable efficacy or adverse outcomes across patient populations. As a result, nanotherapeutic interventions that show promise in controlled preclinical settings may fail to achieve consistent outcomes in broader clinical contexts.

From a translational standpoint, manufacturing and scalability pose additional obstacles. The production of nanomaterials with precise physicochemical properties—such as particle size, surface charge, morphology, and drug-loading efficiency—requires sophisticated techniques that are often difficult to scale without compromising quality. Batch-to-batch variability remains a persistent issue, affecting reproducibility, stability, and therapeutic performance[54]. These manufacturing challenges are closely linked to regulatory hurdles, as stringent quality control and standardization are essential for approval by regulatory agencies. Currently, the lack of universally accepted regulatory guidelines specific to nanomedicine further complicates the approval process and delays clinical implementation[54].

Furthermore, despite a growing body of experimental data, most available evidence remains largely preclinical. Findings are predominantly derived from in vitro assays and animal models, which do not fully replicate the complexity of human inflammatory diseases. Differences in immune system function, metabolism, and disease progression between animal models and humans limit the direct translatability of these results[55]. Consequently, there is a pressing need for well-designed, large-scale clinical trials to rigorously evaluate long-term safety, pharmacokinetics, biodistribution, and therapeutic efficacy in human populations.

Addressing these multifaceted challenges will require interdisciplinary collaboration among material scientists, clinicians, pharmacologists, toxicologists, and regulatory experts. The development of standardized evaluation frameworks for safety, efficacy, and quality control is essential to ensure consistency across studies and facilitate regulatory approval. Additionally, integrating personalized medicine approaches, such as patient stratification based on inflammatory biomarkers and genetic profiles, may enhance therapeutic precision and improve clinical outcomes. Through coordinated efforts and systematic validation, the full clinical potential of these advanced therapeutic strategies can be more effectively realized.

CONCLUSION

Inflammation-responsive nanomaterials represent a powerful and innovative strategy for controlled drug release in obesity-related chronic inflammatory states. By exploiting the unique biochemical features of inflamed tissues, these smart nanocarriers enable precise, site-specific therapy while minimizing systemic toxicity. Advances in material design, multi-stimuli responsiveness, and immune targeting have demonstrated significant therapeutic potential in preclinical models of obesity and metabolic disease. However, successful clinical translation will depend on addressing safety, scalability, and regulatory challenges. With continued technological refinement and rigorous clinical validation, inflammation-responsive nanomedicine may redefine the management of

obesity-associated inflammation and its metabolic consequences, paving the way toward more effective and personalized therapeutic interventions.

REFERENCES

1. Alanazi, A., Craven, A., Spirou, S.V., Santos-Martinez, M.J., Medina, C., Gobbo, O.L.: Nanomedicine as a Promising Treatment Approach for Obesity. J. Nanotheranostics. 6, (2025). https://doi.org/10.3390/jnt6030021
2. Alum, E.U.: Metabolic memory in obesity: Can early-life interventions reverse lifelong risks? Obes. Med. 55, 100610 (2025). https://doi.org/10.1016/j.obmed.2025.100610
3. Barber, T.M., Kyrou, I., Randeva, H.S., Weickert, M.O.: Mechanisms of Insulin Resistance at the Crossroad of Obesity with Associated Metabolic Abnormalities and Cognitive Dysfunction. Int. J. Mol. Sci. 22, 546 (2021). https://doi.org/10.3390/ijms22020546
4. Umoru, G.U., Atangwho, I.J., David-Oku, E., Uti, D.E., De Campos, O.C., Udeozor, P.A., Nfona, S.O., Lawal, B., Alum, E.U.: Modulation of Lipogenesis by Tetracarpidium conophorum Nuts via SREBP-1/ACCA-1/FASN Inhibition in Monosodium-Glutamate-Induced Obesity in Rats. Nat. Prod. Commun. 20, 1934578X251344035 (2025). https://doi.org/10.1177/1934578X251344035
5. Agwupuye, E.I., Obeten, U.N., Maitra, S., Subramaniyan, V., Wong, L.S., Aljarba, N.H., Kumarasamy, V.: Tetracarpidium conophorum nuts (African walnuts) up-regulated adiponectin and PPAR-γ expressions with reciprocal suppression of TNF-α gene in obesity. J. Cell. Mol. Med. 28, e70086 (2024). https://doi.org/10.1111/jcmm.70086
6. Almohaimeed, H.M., Almars, A.I., Tounsi, W.A., Mohammedsaleh, Z.M., Panigrahi, R., Singh, I., Singh, S., Dhara, B., Uti, D.E.: Exosomes in Autoimmunity: Mediators of Autoantigen Presentation and Targets for Therapeutic Intervention in Autoimmune Diseases. J. Clin. Immunol. 46, 3 (2025). https://doi.org/10.1007/s10875-025-01965-0
7. Wokoma, M.A., Oplekwu, R.I., Atangwho, I.J., Egbung, G.E.: Targeting CD44-Hyaluronic Acid Signalling in Obesity Treatment: Insights from Small Molecules and Nanobioconjugates. Nutr. Metab. Insights. 19, 11786388251408961 (2026). https://doi.org/10.1177/11786388251408961
8. Uti, D.E., Omang, W.A., Alum, E.U., Ugwu, O.P.-C., Wokoma, M.A., Oplekwu, R.I., Atangwho, I.J., Egbung, G.E.: Combined Hyaluronic Acid Nanobioconjugates Impair CD44-Signaling for Effective Treatment Against Obesity: A Review of Comparison with Other Actors. Int. J. Nanomedicine. 20, 10101–10126 (2025). https://doi.org/10.2147/IJN.S529250
9. Choe, S.S., Huh, J.Y., Hwang, I.J., Kim, J.I., Kim, J.B.: Adipose Tissue Remodeling: Its Role in Energy Metabolism and Metabolic Disorders. Front. Endocrinol. 7, 30 (2016). https://doi.org/10.3389/fendo.2016.00030
10. Obeten, U.N., Udeozor, P.A., Agada, S.A., Bawa, I., Ogbu, C.O.: Cytokines as key players in obesity low grade inflammation and related complications. Obes. Med. 54, 100585 (2025). https://doi.org/10.1016/j.obmed.2025.100585
11. Ashour, M.M., Mabrouk, M., Aboelnasr, M.A., Beherei, H.H., Tohamy, K.M., Das, D.B.: Anti-Obesity Drug Delivery Systems: Recent Progress and Challenges. Pharmaceutics. 15, 2635 (2023). https://doi.org/10.3390/pharmaceutics15112635
12. Alum, E.U., Izah, S.C., Betiang, P.A., Paul-Chima Ugwu, O., Ainebyoona, C., Uti, D.E., Echegu, D.A., Alum, B.N.: The Ketogenic Diet in Obesity Management: Friend or Foe? Cell Biochem. Biophys. (2025). https://doi.org/10.1007/s12013-025-01878-0
13. Park, C., Kim, Y., Raygani, S., Grunvald, E.: A glimpse into the pipeline of anti-obesity medication development: combining multiple receptor pathways. Front. Endocrinol. 16, (2025). https://doi.org/10.3389/fendo.2025.1630199
14. Alghamdi, M.A., Fallica, A.N., Virzì, N., Kesharwani, P., Pittalà, V., Greish, K.: The Promise of Nanotechnology in Personalized Medicine. J. Pers. Med. 12, 673 (2022). https://doi.org/10.3390/jpm12050673
15. Azmi, N.A.N., Elgharbawy, A.A.M.: Advances in Medical Applications: The Quest of Green Nanomaterials. In: Shanker, U., Hussain, C.M., and Rani, M. (eds.) Handbook of Green and Sustainable Nanotechnology: Fundamentals, Developments and Applications. pp. 1889–1909. Springer International Publishing, Cham (2023)
16. Ghadami, A., Fathi-karkan, S., Siddiqui, B., Gondal, S.A., Rahdar, A., Garousi, N.A., Kharaba, Z., Ghotekar, S.: Nanotechnology in Imatinib delivery: advancing cancer treatment through innovative nanoparticles. Med. Oncol. 42, 116 (2025). https://doi.org/10.1007/s12032-025-02660-1
17. Ntaobeten, E., Obeten, U.N., Bawa, I., Agada, S.A., Ukam, C.I.-O., Egbung, G.E.: Antioxidants in cancer therapy mitigating lipid peroxidation without compromising treatment through nanotechnology. Discov. Nano. 20, 70 (2025). https://doi.org/10.1186/s11671-025-04248-0
18. Alexaki, V.I.: Adipose tissue-derived mediators of systemic inflammation and metabolic control. Curr. Opin. Endocr. Metab. Res. 37, 100560 (2024). https://doi.org/10.1016/j.coemr.2024.100560

19. Bensussen, A., Torres-Magallanes, J.A., Roces De Álvarez-Buylla, E.: Molecular tracking of insulin resistance and inflammation development on visceral adipose tissue. Front. Immunol. 14, 1014778 (2023). https://doi.org/10.3389/fimmu.2023.1014778
20. Bhat, A.A., Uppada, S., Achkar, I.W., Hashem, S., Yadav, S.K., Shanmugakonar, M., Al-Naemi, H.A., Haris, M., Uddin, S.: Tight Junction Proteins and Signaling Pathways in Cancer and Inflammation: A Functional Crosstalk. Front. Physiol. 9, 1942 (2019). https://doi.org/10.3389/fphys.2018.01942
21. da Cruz Nascimento, S.S., Carvalho de Queiroz, J.L., Fernandes de Medeiros, A., de França Nunes, A.C., Piuvezam, G., Lima Maciel, B.L., Souza Passos, T., Morais, A.H. de A.: Anti-inflammatory agents as modulators of the inflammation in adipose tissue: A systematic review. PLoS ONE. 17, e0273942 (2022). https://doi.org/10.1371/journal.pone.0273942
22. Minihane, A.M., Vinoy, S., Russell, W.R., Baka, A., Roche, H.M., Tuohy, K.M., Teeling, J.L., Blaak, E.E., Fenech, M., Vauzour, D., McArdle, H.J., Kremer, B.H.A., Sterkman, L., Vafeiadou, K., Benedetti, M.M., Williams, C.M., Calder, P.C.: Low-grade inflammation, diet composition and health: current research evidence and its translation. Br. J. Nutr. 114, 999–1012 (2015). https://doi.org/10.1017/S0007114515002093
23. Gkrinia, E.M.M., Belančić, A.: The Mechanisms of Chronic Inflammation in Obesity and Potential Therapeutic Strategies: A Narrative Review. Curr. Issues Mol. Biol. 47, 357 (2025). https://doi.org/10.3390/cimb47050357
24. Lee, Y.S., Kim, J., Osborne, O., Oh, D.Y., Sasik, R., Schenk, S., Chen, A., Chung, H., Murphy, A., Watkins, S.M., Quehenberger, O., Johnson, R.S., Olefsky, J.M.: Increased Adipocyte O2 Consumption Triggers HIF-1α Causing Inflammation and Insulin Resistance in Obesity. Cell. 157, 1339–1352 (2014). https://doi.org/10.1016/j.cell.2014.05.012
25. Dahdah, N., Tercero-Alcázar, C., Malagón, M.M., Garcia-Roves, P.M., Guzmán-Ruiz, R.: Interrelation of adipose tissue macrophages and fibrosis in obesity. Biochem. Pharmacol. 225, 116324 (2024). https://doi.org/10.1016/j.bcp.2024.116324
26. Aloh, H., Obasi, D., Okoroh, P., Aniokete, U., & Emeruwa, A. (2025). Maternal Nutrition, Toxicants, and Epigenetic Programming of Obesity Across Generations. Diabetes Metabolic Syndrome and Obesity, Volume 18, 4873-4911. https://doi.org/10.2147/dmso.s579409
27. Ejemot-Nwadiaro, R.I., Betiang, P.A., Basajja, M.: Obesity and Climate Change: A Two-way Street with Global Health Implications. Obes. Med. 100623 (2025). https://doi.org/10.1016/j.obmed.2025.100623
28. Fu, Y., Wang, B., Alu, A., Hong, W., Lei, H., He, X., Shi, H., Cheng, P., Yang, X.: Immunosenescence: signaling pathways, diseases and therapeutic targets. Signal Transduct. Target. Ther. 10, 250 (2025). https://doi.org/10.1038/s41392-025-02371-z
29. Hegde, M., Mishra, A., Banerjee, R., Bintee, B., Alqahtani, M.S., Abbas, M., Shanmugam, M.K., Drum, C.L., Sethi, G., Liu, L., Kunnumakkara, A.B.: Bioresponsive engineered nanoparticles for immunomodulation. BMC Med. 23, 595 (2025). https://doi.org/10.1186/s12916-025-04305-6
30. Hou, J., Xue, Z., Chen, Y., Li, J., Yue, X., Zhang, Y., Gao, J., Hao, Y., Shen, J.: Development of Stimuli-Responsive Polymeric Nanomedicines in Hypoxic Tumors and Their Therapeutic Promise in Oral Cancer. Polymers. 17, (2025). https://doi.org/10.3390/polym17081010
31. Sargazi, S., Barani, M., Zargari, F., Arshad, R., K. Sharma, R.: Preparation of pH-Responsive Vesicular Doxorubicin: Evidence from In-Vitro and In-Silico Evaluations. Curr. Appl. Sci. 2, 31–48 (2024). https://doi.org/10.22034/cas.2022.346726.1024
32. Hajjar, S., Zhou, X.: pH sensing at the intersection of tissue homeostasis and inflammation. Trends Immunol. 44, 807–825 (2023). https://doi.org/10.1016/j.it.2023.08.008
33. Liu, H., Yang, F., Chen, W., Gong, T., Zhou, Y., Dai, X., Leung, W., Xu, C.: Enzyme-Responsive Materials as Carriers for Improving Photodynamic Therapy. Front. Chem. 9, 763057 (2021). https://doi.org/10.3389/fchem.2021.763057
34. Khan, S., Huda, B., Bhurka, F., Patnaik, R., Banerjee, Y.: Molecular and Immunomodulatory Mechanisms of Statins in Inflammation and Cancer Therapeutics with Emphasis on the NF-κB, NLRP3 Inflammasome, and Cytokine Regulatory Axes. Int. J. Mol. Sci. 26, (2025). https://doi.org/10.3390/ijms26178429
35. Ray, A., Cleary, M.P.: The Potential Role of Leptin in Tumor Invasion and Metastasis. Cytokine Growth Factor Rev. 38, 80–97 (2017). https://doi.org/10.1016/j.cytogfr.2017.11.002
36. Sibuyi, N.R.S., Moabelo, K.L., Meyer, M., Onani, M.O., Dube, A., Madiehe, A.M.: Nanotechnology advances towards development of targeted-treatment for obesity. J. Nanobiotechnology. 17, 122 (2019). https://doi.org/10.1186/s12951-019-0554-3
37. Stevanović, M.M., Qian, K., Huang, L., Vukomanović, M.: PLGA-Based Co-Delivery Nanoformulations: Overview, Strategies, and Recent Advances. Pharmaceutics. 17, 1613 (2025). https://doi.org/10.3390/pharmaceutics17121613
38. Swider, E., Koshkina, O., Tel, J., Cruz, L.J., de Vries, I.J.M., Srinivas, M.: Customizing poly(lactic-*co*-glycolic acid) particles for biomedical applications. Acta Biomater. 73, 38–51 (2018). https://doi.org/10.1016/j.actbio.2018.04.006

39. Atangwho, I.J., Ugwu, O.P.-C., Egbung, G.E., Aja, P.M.: Lipid-based nano-carriers for the delivery of anti-obesity natural compounds: advances in targeted delivery and precision therapeutics. J. Nanobiotechnology. 23, 336 (2025). https://doi.org/10.1186/s12951-025-03412-z
40. Yun, Y., An, J., Kim, H.J., Choi, H.K., Cho, H.-Y.: Recent advances in functional lipid-based nanomedicines as drug carriers for organ-specific delivery. Nanoscale. (2025). https://doi.org/10.1039/D4NR04778H
41. Nwuruku, O.A., Ugwu, O.P.-C., Uti, D.E., Edwin, N.: Harnessing nature: plant-derived nanocarriers for targeted drug delivery in cancer therapy. Phytomedicine Plus. 5, 100828 (2025). https://doi.org/10.1016/j.phyplu.2025.100828
42. Liu, Y., Zhao, M., Zhang, M., Yang, B., Qi, Y.-K., Fu, Q.: Mesoporous silica nanoparticle-based nanomedicine: Preparation, functional modification, and theranostic applications. Mater. Today Bio. 34, 102223 (2025). https://doi.org/10.1016/j.mtbio.2025.102223
43. Kianfar, E., Kadhum, W.R., Mahmoud, Z.H.: Hydrogel Nanoparticles in Drug Delivery: A Review. Intell. Pharm. (2025). https://doi.org/10.1016/j.ipha.2025.11.002
44. Alanazi, A., Craven, A., Spirou, S.V., Santos-Martinez, M.J., Medina, C., Gobbo, O.L.: Nanomedicine as a Promising Treatment Approach for Obesity. J. Nanotheranostics. 6, (2025). https://doi.org/10.3390/jnt6030021
45. Ghlichloo, I., Gerriets, V.: Nonsteroidal Anti-Inflammatory Drugs (NSAIDs). In: StatPearls. StatPearls Publishing, Treasure Island (FL) (2025)
46. Aloo, S.O., Barathikannan, K., Oh, D.-H.: Polyphenol-rich fermented hempseed ethanol extracts improve obesity, oxidative stress, and neural health in high-glucose diet-induced *Caenorhabditis elegans*. Food Chem. X. 21, 101233 (2024). https://doi.org/10.1016/j.fochx.2024.101233
47. Mahjabeen, W., Khan, D.A., Mirza, S.A.: Role of resveratrol supplementation in regulation of glucose hemostasis, inflammation and oxidative stress in patients with diabetes mellitus type 2: A randomized, placebo-controlled trial. Complement. Ther. Med. 66, 102819 (2022). https://doi.org/10.1016/j.ctim.2022.102819
48. Rudrapal, M., Khairnar, S.J., Khan, J., Dukhyil, A.B., Ansari, M.A., Alomary, M.N., Alshabrmi, F.M., Palai, S., Deb, P.K., Devi, R.: Dietary Polyphenols and Their Role in Oxidative Stress-Induced Human Diseases: Insights Into Protective Effects, Antioxidant Potentials and Mechanism(s) of Action. Front. Pharmacol. 13, 806470 (2022). https://doi.org/10.3389/fphar.2022.806470
49. Thiruvengadam, R., Kondapavuluri, B.K., Thangavelu, L., Thiruvengadam, M., Hatami, M., Kim, J.H.: Nanoparticle-based strategies with bioactive compounds for targeting oxidative stress in therapeutic interventions: A comprehensive review. Ind. Crops Prod. 227, 120804 (2025). https://doi.org/10.1016/j.indcrop.2025.120804
50. Souto, E.B., Souto, S.B., Campos, J.R., Severino, P., Pashirova, T.N., Zakharova, L.Y., Silva, A.M., Durazzo, A., Lucarini, M., Izzo, A.A., Santini, A.: Nanoparticle Delivery Systems in the Treatment of Diabetes Complications. Molecules. 24, 4209 (2019). https://doi.org/10.3390/molecules24234209
51. Saha, P., Sharma, S.S.: RNA Interference Unleashed: Current Perspective of Small Interfering RNA (siRNA) Therapeutics in the Treatment of Neuropathic Pain. ACS Pharmacol. Transl. Sci. 7, 2951−2970 (2024). https://doi.org/10.1021/acsptsci.4c00329
52. Elmowafy, E.M., Tiboni, M., Soliman, M.E.: Biocompatibility, biodegradation and biomedical applications of poly(lactic acid)/poly(lactic-co-glycolic acid) micro and nanoparticles. J. Pharm. Investig. 49, 347−380 (2019). https://doi.org/10.1007/s40005-019-00439-x
53. Xuan, L., Ju, Z., Skonieczna, M., Zhou, P., Huang, R.: Nanoparticles-induced potential toxicity on human health: Applications, toxicity mechanisms, and evaluation models. MedComm. 4, e327 (2023). https://doi.org/10.1002/mco2.327
54. Bi, Y., Xie, S., Li, Z., Dong, S., Teng, L.: Precise nanoscale fabrication technologies, the "last mile" of medicinal development. Acta Pharm. Sin. B. 15, 2372−2401 (2025). https://doi.org/10.1016/j.apsb.2025.03.040
55. Reza Khorramizadeh, M., Saadat, F.: Animal models for human disease. Anim. Biotechnol. 153−171 (2020). https://doi.org/10.1016/B978-0-12-811710-1.00008-2

CITE AS: Muhindo Edgar (2026). Inflammation-Responsive Nanomaterials for Controlled Drug Release in Obesity-Related Chronic Inflammatory States. NEWPORT INTERNATIONAL JOURNAL OF SCIENTIFIC AND EXPERIMENTAL SCIENCES, 7(2):16-22. https://doi.org/10.59298/NIJSES/2026/72.1622